Dr. Radhika Tripuraneni is a seasoned biopharmaceutical leader serving as Chief Scientific Officer at Viridian Therapeutics ORS Inc., a pioneering company focused on developing transformative therapies for liver and metabolic diseases. With more than 25 years of experience in drug discovery and development, she previously held senior roles at Allergan and Gilead Sciences, where she led cross-functional teams in advancing clinical-stage assets from preclinical stages through regulatory approval. Dr. Tripuraneni earned her PhD in Molecular Biology from the University of California, Berkeley, and completed postdoctoral training at the National Institutes of Health, establishing a strong foundation in translational research. Her notable achievements include spearheading the development of two FDA-approved therapies for rare genetic disorders, securing over $150 million in grant funding from the NIH and private foundations, and co-authoring more than 40 peer-reviewed publications in top journals such as Nature Medicine and Cell Metabolism. She holds multiple patents in gene therapy and small-molecule inhibitors, reflecting her innovative approach to tackling unmet medical needs. At Viridian Therapeutics ORS Inc., Dr. Tripuraneni drives the scientific strategy, overseeing a robust pipeline of investigational treatments targeting alpha-1 antitrypsin deficiency and other orphan indications, positioning the company as a leader in precision medicine.